Skip to main content
Top
Published in: Diabetologia 4/2006

01-04-2006 | Article

Mitochondria are impaired in the adipocytes of type 2 diabetic mice

Authors: H.-J. Choo, J.-H. Kim, O.-B. Kwon, C. S. Lee, J. Y. Mun, S. S. Han, Y.-S. Yoon, G. Yoon, K.-M. Choi, Y.-G. Ko

Published in: Diabetologia | Issue 4/2006

Login to get access

Abstract

Aims/hypothesis

The aim of this study was to confirm a link between mitochondrial dysfunction and type 2 diabetes.

Materials and methods

Cellular levels of mitochondrial proteins, cellular mitochondrial DNA content, and mitochondrial function and morphology were assessed by MitoTracker staining and electron microscopy, in white adipose tissue of 12-week-old male wild-type, obese (ob/ob), and diabetic (db/db) mice.

Results

Levels of mitochondrial proteins were found to be very similar in the livers and muscles of all the mice studied. However, levels were greatly decreased in the adipocytes of db/db mice, but not in those of the wild-type and ob/ob mice. Levels of mitochondrial DNA were also found to be considerably reduced in the adipocytes of db/db mice. MitoTracker staining and under electron microscopy revealed that the number of mitochondria was reduced in adipocytes of db/db mice. Respiration and fatty acid oxidation studies indicated mitochondrial dysfunction in adipocytes of db/db mice. Interestingly, there was an increase in mitochondria and mitochondrial protein production in adipocytes of db/db mice treated with rosiglitazone, an agent that enhances insulin sensitivity.

Conclusions/interpretation

Taken together, these data indicate that mitochondrial loss in adipose tissue is correlated with the development of type 2 diabetes.
Appendix
Available only for authorised users
Literature
1.
go back to reference Moller DE (2001) New drug targets for type 2 diabetes and the metabolic syndrome. Nature 414:821–827CrossRefPubMed Moller DE (2001) New drug targets for type 2 diabetes and the metabolic syndrome. Nature 414:821–827CrossRefPubMed
3.
go back to reference Janson J, Laedtke T, Parisi JE, O’Brien P, Petersen RC, Butler PC (2004) Increased risk of type 2 diabetes in Alzheimer disease. Diabetes 53:474–481PubMedCrossRef Janson J, Laedtke T, Parisi JE, O’Brien P, Petersen RC, Butler PC (2004) Increased risk of type 2 diabetes in Alzheimer disease. Diabetes 53:474–481PubMedCrossRef
4.
go back to reference Schrauwen P, Hesselink MK (2004) Oxidative capacity, lipotoxicity, and mitochondrial damage in type 2 diabetes. Diabetes 53:1412–1417PubMedCrossRef Schrauwen P, Hesselink MK (2004) Oxidative capacity, lipotoxicity, and mitochondrial damage in type 2 diabetes. Diabetes 53:1412–1417PubMedCrossRef
5.
go back to reference Taylor R (2004) Causation of type 2 diabetes—the Gordian knot unravels. N Engl J Med 350:639–641CrossRefPubMed Taylor R (2004) Causation of type 2 diabetes—the Gordian knot unravels. N Engl J Med 350:639–641CrossRefPubMed
6.
go back to reference Hojlund K, Wrzesinski K, Larsen PM et al (2003) Proteome analysis reveals phosphorylation of ATP synthase beta-subunit in human skeletal muscle and proteins with potential roles in type 2 diabetes. J Biol Chem 278:10436–10442PubMedCrossRef Hojlund K, Wrzesinski K, Larsen PM et al (2003) Proteome analysis reveals phosphorylation of ATP synthase beta-subunit in human skeletal muscle and proteins with potential roles in type 2 diabetes. J Biol Chem 278:10436–10442PubMedCrossRef
7.
go back to reference Kelley DE, He J, Menshikova EV, Ritov VB (2002) Dysfunction of mitochondria in human skeletal muscle in type 2 diabetes. Diabetes 51:2944–2950PubMedCrossRef Kelley DE, He J, Menshikova EV, Ritov VB (2002) Dysfunction of mitochondria in human skeletal muscle in type 2 diabetes. Diabetes 51:2944–2950PubMedCrossRef
8.
go back to reference Ritov VB, Menshikova EV, He J, Ferrell RE, Goodpaster BH, Kelley DE (2005) Deficiency of subsarcolemmal mitochondria in obesity and type 2 diabetes. Diabetes 54:8–14PubMedCrossRef Ritov VB, Menshikova EV, He J, Ferrell RE, Goodpaster BH, Kelley DE (2005) Deficiency of subsarcolemmal mitochondria in obesity and type 2 diabetes. Diabetes 54:8–14PubMedCrossRef
9.
go back to reference Petersen KF, Befroy D, Dufour S et al (2003) Mitochondrial dysfunction in the elderly: possible role in insulin resistance. Science 300:1140–1142CrossRefPubMed Petersen KF, Befroy D, Dufour S et al (2003) Mitochondrial dysfunction in the elderly: possible role in insulin resistance. Science 300:1140–1142CrossRefPubMed
10.
go back to reference Petersen KF, Dufour S, Befroy D, Garcia R, Shulman GI (2004) Impaired mitochondrial activity in the insulin-resistant offspring of patients with type 2 diabetes. N Engl J Med 350:664–671CrossRefPubMed Petersen KF, Dufour S, Befroy D, Garcia R, Shulman GI (2004) Impaired mitochondrial activity in the insulin-resistant offspring of patients with type 2 diabetes. N Engl J Med 350:664–671CrossRefPubMed
11.
go back to reference Abel ED, Peroni O, Kim JK et al (2001) Adipose-selective targeting of the GLUT4 gene impairs insulin action in muscle and liver. Nature 409:729–733CrossRefPubMed Abel ED, Peroni O, Kim JK et al (2001) Adipose-selective targeting of the GLUT4 gene impairs insulin action in muscle and liver. Nature 409:729–733CrossRefPubMed
12.
go back to reference Evans RM, Barish GD, Wang Y-X (2004) PPARs and the complex journey to obesity. Nat Med 10:355–361CrossRefPubMed Evans RM, Barish GD, Wang Y-X (2004) PPARs and the complex journey to obesity. Nat Med 10:355–361CrossRefPubMed
13.
go back to reference Fasshauer M, Paschke R (2003) Regulation of adipocytokines and insulin resistance. Diabetologia 46:1594–1603CrossRefPubMed Fasshauer M, Paschke R (2003) Regulation of adipocytokines and insulin resistance. Diabetologia 46:1594–1603CrossRefPubMed
14.
15.
go back to reference Yamauchi T, Kamon J, Minokoshi Y et al (2002) Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase. Nat Med 8:1288–1295PubMedCrossRef Yamauchi T, Kamon J, Minokoshi Y et al (2002) Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase. Nat Med 8:1288–1295PubMedCrossRef
16.
go back to reference Banerjee RR, Rangwala SM, Shapiro JS et al (2004) Regulation of fasted blood glucose by resistin. Science 303:1195–1198CrossRefPubMed Banerjee RR, Rangwala SM, Shapiro JS et al (2004) Regulation of fasted blood glucose by resistin. Science 303:1195–1198CrossRefPubMed
17.
go back to reference Hotamisligil GS, Peraldi P, Budavari A, Ellis R, White MF, Spiegelman BM (1996) IRS-1-mediated inhibition of insulin receptor tyrosine kinase activity in TNFα and obesity-induced insulin resistance. Science 271:665–668PubMedCrossRef Hotamisligil GS, Peraldi P, Budavari A, Ellis R, White MF, Spiegelman BM (1996) IRS-1-mediated inhibition of insulin receptor tyrosine kinase activity in TNFα and obesity-induced insulin resistance. Science 271:665–668PubMedCrossRef
18.
go back to reference Wilson-Fritch L, Burkart A, Bell G et al (2003) Mitochondrial biogenesis and remodeling during adipogenesis and in response to the insulin sensitizer rosiglitazone. Mol Cell Biol 23:1085–1094CrossRefPubMed Wilson-Fritch L, Burkart A, Bell G et al (2003) Mitochondrial biogenesis and remodeling during adipogenesis and in response to the insulin sensitizer rosiglitazone. Mol Cell Biol 23:1085–1094CrossRefPubMed
19.
go back to reference Kim B-W, Choo H-J, Lee J-W, Kim J-H, Ko Y-G (2004) Extracellular ATP is generated by ATP synthase complex in adipocyte lipid rafts. Exp Mol Med 36:476–485PubMed Kim B-W, Choo H-J, Lee J-W, Kim J-H, Ko Y-G (2004) Extracellular ATP is generated by ATP synthase complex in adipocyte lipid rafts. Exp Mol Med 36:476–485PubMed
20.
go back to reference Wilson-Fritch L, Nicoloro S, Chouinard M et al (2004) Mitochondrial remodeling in adipose tissue associated with obesity and treatment with rosiglitazone. J Clin Invest 114:1281–1289CrossRefPubMed Wilson-Fritch L, Nicoloro S, Chouinard M et al (2004) Mitochondrial remodeling in adipose tissue associated with obesity and treatment with rosiglitazone. J Clin Invest 114:1281–1289CrossRefPubMed
21.
go back to reference Kanemoto N, Hishigaki H, Miyakita A et al (1998) Genetic dissection of “OLETF”, a rat model for non-insulin-dependent diabetes mellitus. Mamm Genome 9:419–425CrossRefPubMed Kanemoto N, Hishigaki H, Miyakita A et al (1998) Genetic dissection of “OLETF”, a rat model for non-insulin-dependent diabetes mellitus. Mamm Genome 9:419–425CrossRefPubMed
22.
go back to reference Antonicka H, Ogilvie I, Taivassalo T et al (2003) Identification and characterization of a common set of complex I assembly intermediates in mitochondria from patients with complex I deficiency. J Biol Chem 278:43081–43088CrossRefPubMed Antonicka H, Ogilvie I, Taivassalo T et al (2003) Identification and characterization of a common set of complex I assembly intermediates in mitochondria from patients with complex I deficiency. J Biol Chem 278:43081–43088CrossRefPubMed
23.
go back to reference Wu Z, Puigserver P, Andersson U et al (1999) Mechanisms controlling mitochondrial biogenesis and respiration through the thermogenic coactivator PGC-1. Cell 98:115–124CrossRefPubMed Wu Z, Puigserver P, Andersson U et al (1999) Mechanisms controlling mitochondrial biogenesis and respiration through the thermogenic coactivator PGC-1. Cell 98:115–124CrossRefPubMed
24.
go back to reference Lehman JJ, Barger PM, Kovacs A, Saffitz JE, Medeiros DM, Kelly DP (2000) Peroxisome proliferator-activated receptor gamma coactivator-1 promotes cardiac mitochondrial biogenesis. J Clin Invest 106:847–856PubMedCrossRef Lehman JJ, Barger PM, Kovacs A, Saffitz JE, Medeiros DM, Kelly DP (2000) Peroxisome proliferator-activated receptor gamma coactivator-1 promotes cardiac mitochondrial biogenesis. J Clin Invest 106:847–856PubMedCrossRef
25.
go back to reference Lin J, Wu H, Tarr PT et al (2002) Transcriptional co-activator PGC-1 alpha drives the formation of slow-twitch muscle fibres. Nature 418:797–801CrossRefPubMed Lin J, Wu H, Tarr PT et al (2002) Transcriptional co-activator PGC-1 alpha drives the formation of slow-twitch muscle fibres. Nature 418:797–801CrossRefPubMed
26.
go back to reference Lin J, W P-H, Tarr PT et al (2004) Defects in adaptive energy metabolism with CNS-linked hyperactivity in PGC-1alpha null mice. Cell 119:121–135CrossRefPubMed Lin J, W P-H, Tarr PT et al (2004) Defects in adaptive energy metabolism with CNS-linked hyperactivity in PGC-1alpha null mice. Cell 119:121–135CrossRefPubMed
27.
go back to reference Kakuma T, Wang ZW, Pan W, Unger RH, Zhou YT (2000) Role of leptin in peroxisome proliferator-activated receptor gamma coactivator-1 expression. Endocrinology 141:4576–4582CrossRefPubMed Kakuma T, Wang ZW, Pan W, Unger RH, Zhou YT (2000) Role of leptin in peroxisome proliferator-activated receptor gamma coactivator-1 expression. Endocrinology 141:4576–4582CrossRefPubMed
Metadata
Title
Mitochondria are impaired in the adipocytes of type 2 diabetic mice
Authors
H.-J. Choo
J.-H. Kim
O.-B. Kwon
C. S. Lee
J. Y. Mun
S. S. Han
Y.-S. Yoon
G. Yoon
K.-M. Choi
Y.-G. Ko
Publication date
01-04-2006
Publisher
Springer-Verlag
Published in
Diabetologia / Issue 4/2006
Print ISSN: 0012-186X
Electronic ISSN: 1432-0428
DOI
https://doi.org/10.1007/s00125-006-0170-2

Other articles of this Issue 4/2006

Diabetologia 4/2006 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.